Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 12,286 shares at $1.81 ($22K) on 2023-02-03, disclosed to the SEC on 2023-02-06.
Open-market sale of $22k SPRO by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |